Transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve repair (TMVR) are increasingly used for managing patients with valvular heart disease to whom surgery presents a high-risk. As these are costly procedures, a systematic review of studies concerned with their economic assessment was undertaken. The search was performed in PubMed and the Cochrane Library and followed recommended methodological steps. Studies were screened and their data were retrieved and were synthesized using a narrative approach. Twenty-four, good to high quality, evaluations were identified, representing different viewpoints, modelling techniques and willingness-topay thresholds. Studies show that in high-risk patients with symptomatic aortic stenosis, TAVI may be cost-effective compared with medical management (MM) across many health care settings. In contrast, studies of TAVI compared with surgical aortic valve replacement (SAVR) yield conflicting and inconclusive results. The limited data available show that TMVR may also be cost-effective relative to MM
Introduction
Valvular heart disease (VHD) is characterized by damage to or a defect in one of the four heart valves: mitral, aortic, tricuspid, or pulmonary. Though less common than coronary artery disease, heart failure, or hypertension, VHD is frequently encountered and often requires intervention. This can be challenging and complex, since it is often observed in older patients who show a higher incidence of comorbidity. 1, 2 The prevalence of VHD in industrialized countries is estimated at 2.5% and increases markedly after the age of 65 years, owing to the predominance of degenerative etiologies. 3 According to the Euro Heart Survey on VHD, the commonest types of VHD in the Europe are aortic stenosis (AS), followed by mitral regurgitation (MR), accounting for 43% and 13%, respectively, of the single native leftsided valve diseases. 1 According to the guidelines issued by the European Society of Cardiology, 4 until recently the standard of treatment for patients with symptomatic severe AS and MR was surgical repair or replacement of the respective valve. Although surgery has been shown to prolong and improve quality of life, 4 a large number of patients are considered unsuitable for surgery because of the presence of multiple comorbidities and the patients' advanced age. In this group of patients at high surgical risk, AS and MR can be treated with transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve repair (TMVR), which are less invasive approaches that have recently emerged as alternative effective treatment options.
Both TAVI and TMVR treatment options have been proven highly effective in terms of improving clinical symptoms and quality of life in patients who are at high risk of surgery [5] [6] [7] [8] ; however, the cost associated with these new interventions is relatively high. Considering that more than 34 000 patients underwent TAVI between 2007 and 2011 in 11 European countries, 9 while more than 10 000 patients have undergone TMVR worldwide, 10 the budget impact associated with these interventions is substantial and is expected to rise further as a result of the aging population. Given the high cost associated with these procedures and the growing number of potential eligible candidates, the evaluation of both their clinical and economic effectiveness through cost-effectiveness analyses is of great importance, especially in relation to decisions about the allocation of scarce health care resources, in an environment of increasing demands due to demographic and technological trends. For this reason, this article aims to systematically review the published literature concerning economic evaluations of interventions in VHD.
Methods

Design and search strategy
This systematic review was carried out in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) standard. 11 The literature search was performed through June 2017. The electronic databases utilized were PubMed and Cochrane, using the following combined search terms: ('valvular heart disease' or 'aortic regurgitation' or 'aortic stenosis' or 'mitral regurgitation' or 'mitral stenosis' or 'tricuspid regurgitation' or 'tricuspid stenosis') and ('cost' or 'economic evaluation' or 'costeffectiveness' or 'cost-benefit' or 'cost-utility'). The search was conducted with no restriction on publication dates. The search was supplemented through internet search engines and reference lists of retrieved articles and reviews.
Study eligibility criteria
To be eligible for inclusion, publications had to: (i) present full economic evaluations of VHD treatment strategies; (ii) report the incremental costeffectiveness ratios (ICERs) as either cost per quality-adjusted life year (QALY) gained or as cost per life-year gained (LYG); and (iii) be published in the English language. Studies were excluded if they were abstracts, editorials, letters, case reports, conference presentations, expert opinions, or reviews.
Data extraction and synthesis
For each included article, the following information was extracted: author, year of publication, country, comparators, model design, time horizon and cycle length, perspective (societal, payer, provider), outcomes measured, source of efficacy data, currency, and year in which costs were evaluated, discounting, funding, effectiveness (QALYs, LYG), costs, ICERs, and willingness-to-pay (WTP) thresholds used. Currencies were not converted into a 'common currency', but instead costs were reported as they appeared in each study. If the year of the cost data was not reported, it was assumed to be the year of article publication. Studies were synthesized through a narrative review with tabulation of the results of the included studies.
Quality assessment
The methodological adequacy and the validity of the results of each included study were assessed using the checklist developed by the British Medical Journal (BMJ), 12 
Results
Number of studies identified
As shown in Figure 1 , the literature search identified 23 potentially eligible articles to be included. Four additional articles were added through the internet and reference list search, of which three were health technology assessment reports overlapping with two of the articles already included; thus, they were excluded. Ultimately, a total of 24 studies were considered in this systematic review.
General characteristics of included studies
The 24 studies, published between 2012 and June 2017, are summarized in Table 1 . The majority are focused on the economic evaluation of TAVI compared with medical management (MM) and/or surgical aortic valve replacement (SAVR) in patients with severe AS, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] while the remainder focused on the economic evaluation of mitral valve repair (MVR) compared with MM in patients with severe MR. [32] [33] [34] [35] [36] [37] In terms of setting, the majority of the studies were conducted in the UK 15, 17, 18, 22, 24, 31, 37 and the USA. 19, 20, [26] [27] [28] 30 Four were conducted in Canada 16, 21, 33, 35 and one each in Belgium, 23 Germany, 34 Spain, 29 the Netherlands, 25 Italy, 32 and France. 36 Economic evaluations represented all possible perspectives: provider, societal, and third-party payer. The majority of the studies used a Markov model, [14] [15] [16] [17] 19, 20, 22, 23, [30] [31] [32] [34] [35] [36] [37] with three studies using trial-based analysis, [26] [27] [28] while in two studies the modelling method was not explicit. 29, 33 The time horizons of all studies varied from 12 months to lifetime. Efficacy data to inform the clinical parameters of the models were derived from the PARTNER trials 6, 38 in the majority of the studies concerning the cost-effectiveness of TAVI, while in the two most recent studies by Brecker et al. 15 and Reynolds et al. 26 data were derived from Key points for decision makers
• Economic evaluations of transcatheter aortic valve implantation (TAVI) compared with medical management for inoperable patients with symptomatic aortic stenosis report favourable cost-effectiveness ratios in selected health care settings.
• The cost-effectiveness of TAVI compared with surgical aortic valve replacement in high-risk operable patients, based on the current data, is uncertain and depends on the access route (transfemoral or transapical) and the procedural costs.
• Though mitral valve repair is a promising technique, available data on its cost-effectiveness are limited; further research will be needed before accurate conclusions can be drawn. 14, [18] [19] [20] 22, 25, 29, 31 Finally, three of the studies concerning the cost-effectiveness of MVR [35] [36] [37] used data from the EVEREST High-Risk study, 8 two studies included registry data 32, 33 and the remaining one 34 used data from the TITAN trial. 41 The associated therapy costs accounted for the device, the procedure, the initial and repeat hospitalizations, drugs used, perioperative and long-term complications, and physicians' fees. These costs were derived from hospital billing data, the literature, government data, and data collected from trials. Costs and benefits were discounted appropriately using country-specific guidance rates, ranging from 3% to 5% for costs and from 1.5% to 5% for benefits. Three studies 25, 27, 29 did not apply a discount rate because of the short follow-up period (12 months), while in one study the reason for not applying discounting was not reported. 22 The year of cost data was spread between 2008 and 2013.
Quality assessment
Supplementary material online, Table S1 summarizes the results of applying the 35-item BMJ 12 checklist to the economic evaluations.
With the exception of one study, 16 which received a score of 25, all others were of good or high quality as they received scores from 27 to 30 out of 35, meaning that very few methodological elements were unmet or not clear. The most common weak points of the studies considered, concern proper justification of discounting rates, the lack of details regarding the statistical analysis, and the incomplete presentation of relevant costs and input parameters.
Cost-effectiveness of transcatheter aortic valve implantation
Transcatheter aortic valve implantation vs. medical management Thirteen studies [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] 28, 30, 31 evaluated the cost-effectiveness of TAVI compared with medical therapy alone ( Table 2) . In general, the results among most studies were in favour of TAVI. Specifically, the projected costs of TAVI-transapical (TA) or transfemoral (TF)-were consistently greater than those of medical therapy; however, in all cases, TAVI was associated with a greater improvement in quality adjusted life years (difference 0.44-1.87 QALYs). Concerning the cost-effectiveness of TAVI compared with MM, the majority of the Table 2) . 14, 16, 17, 19, 20, [23] [24] [25] [26] [27] 29 Results among these studies were divided favouring either the one or the other method and hence they do not support a conclusive superiority of the one over the other treatment method. Specifically, TAVI was reported to be more costly than SAVR in almost all studies, apart from the study by Ribera Medtronic CoreValve balloon-expandable (MC-TAVI) valve analysed and the study by Fairbairn et al. 17 In the last two studies, TAVI was found to dominate SAVR, meaning it was less costly and more effective. In contrast, in five studies TAVI was reported to be dominated by SAVR, 16, 19, 24, 27, 29 meaning it was more costly and less effective.
Moreover, in two studies TAVI was found to be cost-effective, in other words delivering higher benefit at reasonable costs relative to SAVR, with ICERs at US$32 000/QALY 20 and US$55 090/QALY analysis. [26] [27] [28] In contrast, while TAVI was more effective, it was not cost- Table 2) .
Based on the results of these studies, overall the MitraClip treatment resulted in greater LYG, QALYs and costs compared with MM. All studies concluded that the MitraClip treatment constitutes an attractive therapeutic option from an economic viewpoint. Because of the heterogeneity of the settings and health care systems, the differences in the evaluation methodologies and the different populations across studies, it is difficult to make a direct comparison between results from different studies. The generated ICERs, which were most sensitive to the choice of time horizon and thus the benefits associated with the treatment, were under the typical cost per QALY threshold ranges utilized in the USA (US$50 000-US$100 000), UK (£20 000-£30 000), Canadian (C$20 000-C$100 000), and European (e30 000) settings.
Finally, in the study by Borisenko et al. 34 the Carillon Mitral
Contour System compared with MM was associated with higher costs (e36 785 vs. e18 944; 2013 values) and significant benefits, in terms of both QALYs gained (4.06 vs. 2.91, respectively) and LYG (5.87 vs. 4.46, respectively) . This resulted in an ICER of e15 533/ QALY, which is considered cost-effective. In the probabilistic sensitivity analysis, the TMVR arm had an 84% probability of being costeffective under a WTP threshold of e35 000/QALY. 34 
Discussion
This study represents the first published systematic review to assess the cost-effectiveness of the various VHD interventions. In this systematic review we identified 24 economic evaluations, of which 18 considered the cost-effectiveness of TAVI compared with either standard management or SAVR in patients with severe symptomatic AS, while the remaining six considered the cost-effectiveness of TMVR compared with standard management in patients with severe MR and high surgical risk. Overall, the analyses represented a broad range of health care systems, modelling techniques, WTP thresholds. Despite these inherent differences, results across the majority of the studies were consistent in that TAVI compared with MM is economically attractive and below the conventional WTP thresholds of e30 000/QALY and US$50 000/QALY. Only two studies found that TAVI was not costeffective compared with MM. 22, 30 In general, the probability that TAVI may be cost-effective depends largely on the WTP thresholds applied in each study. As demonstrated by Reynolds et al., 28 the probability of TAVI being cost-effective relative to MM ranges from 3% to 100% for different WTP thresholds. At this point it should be noted that the thresholds reported in the literature are in line to those of other widely used techniques within and outside cardiology. In addition, studies showed that the cost-effectiveness of TAVI compared with MM also depends upon patient selection. More specifically, high levels of comorbidity among elderly patients increase health carerelated costs, even after TAVI is implemented successfully. Thus, TAVI may present even better ICERs for healthier patient cohorts, or for patients who are inoperable for technical reasons rather than because of severe comorbidities. 23 Furthermore, TAVI must result in both improved quality of life and gains in life expectancy in order to be cost-effective. 28 More specifically, sensitivity analyses based on the PARTNER trial (Cohort B) showed that, if there was an improvement in quality of life but not in survival, the ICER of TAVI became less favourable at approximately US$83 000/QALY gained. 28 On the other hand, the results concerning the cost-effectiveness of TAVI compared with SAVR were inconsistent among studies. The stratification of TAVI by access route (TF or TA) had an impact on its cost-effectiveness. Specifically, compared with SAVR, the TF-TAVI approach was cost-effective, with lower one-year costs and greater QALY gains, whereas the TA-TAVI approach was associated with higher costs and no clear improvement in quality of life, and thus was dominated by SAVR. Both TF and TA TAVI generated higher procedural costs compared with SAVR, which were attributed to the higher valve acquisition costs; however, TF-TAVI resulted in greater reductions in the length of stay compared with SAVR than did TA-TAVI, which offset the higher procedural costs and thus resulted in a better ICER. Nonetheless, in many studies TAVI was dominated or found to be more effective but too expensive relative to SVAR. Hence, in this light it is inconclusive at this stage whether there are any significant differences in terms of cost-effectiveness in between the two.
There is limited evidence regarding both the clinical benefit and cost-effectiveness of TMVR. To date, there are only six available studies regarding the cost-effectiveness of TMVR, five of which were concerned with the MitraClip system compared with MM in patients with severe MR who were ineligible for surgery, 32, 33, [35] [36] [37] while the remaining one evaluated the novel Carillon Mitral Contour System. 34 Results from these studies, though performed in different settings, demonstrated similar ICERs, which fall below the commonly proposed WTP thresholds. Hence, it may be concluded at this stage that TMVR may be attractive therapy option from an economic point of view, but that needs further reassurance through additional research. Finally, it should be noted that like any reviews of this kind the present study has limitations. It is based on the published literature in the English language. It brings together many studies done with different methods and for different health care systems. As times goes by, learning curves, economies of scale, price reductions due to competition, technological innovations, may have profound effects of the results. Moreover, a quantitative approach, like a meta-analysis for instance, is not feasible for economic studies, and hence the interpretation of the review results is subjective, leaving space for wide interpretations.
Conclusion
To conclude, evidence from this systematic review suggests that, in patients with symptomatic AS who are inoperable, TAVI provides improvements in survival and quality of life, and despite the higher costs, it can be cost-effective compared with MM in selected health care settings and patient groups. However, the cost-effectiveness of TAVI compared with surgical AVR in high-risk operable patients, based on the current data, is uncertain. Some studies show it to dominate, others to be dominated, others to be cost-effective and other not. Hence, is not possible to reach any safe conclusions. The limited evidence available, supports that whether TAVI compared with SAVR is cost-effective may depend on the access route (TF or TA), the procedural cost, and the patients selected, since in general terms TAVI and SAVR have demonstrated similar survival and only small differences in benefit in terms of quality of life. More research is needed in this area. There are limited, but positive data, regarding the costeffectiveness of TMVR; therefore, though this is a promising new area in the treatment of VHD, further research is needed to establish the cost-effectiveness of the procedure and the drivers of it.
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